Frontiers in Immunology (Mar 2025)
Longitudinal analysis of immune responses to SARS-CoV-2 recombinant vaccine S-268019-b in phase 1/2 prime-boost study
- Masaya Fujitani,
- Xiuyuan Lu,
- Ryo Shinnakasu,
- Takeshi Inoue,
- Yujiro Kidani,
- Naomi M. Seki,
- Satoru Ishida,
- Shungo Mitsuki,
- Takeshi Ishihara,
- Miwa Aoki,
- Akio Suzuki,
- Koji Takahashi,
- Masahiro Takayama,
- Takeshi Ota,
- Satoshi Iwata,
- Risa Yokokawa Shibata,
- Takuhiro Sonoyama,
- Mari Ariyasu,
- Ayumi Kitano,
- Tommy Terooatea,
- Jordan Kelly Villa,
- Kazuo Yamashita,
- Sho Yamasaki,
- Sho Yamasaki,
- Sho Yamasaki,
- Tomohiro Kurosaki,
- Tomohiro Kurosaki,
- Shinya Omoto
Affiliations
- Masaya Fujitani
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Xiuyuan Lu
- Laboratory of Molecular Immunology, World Premier International Research Center Initiative (WPI) Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Ryo Shinnakasu
- Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Takeshi Inoue
- Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Yujiro Kidani
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Naomi M. Seki
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Satoru Ishida
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Shungo Mitsuki
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Takeshi Ishihara
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Miwa Aoki
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Akio Suzuki
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Koji Takahashi
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- Masahiro Takayama
- Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., Osaka, Japan
- Takeshi Ota
- Pharmaceutical Technology Research Division, Shionogi & Co., Ltd., Osaka, Japan
- Satoshi Iwata
- Department of Microbiology, Tokyo Medical University, Tokyo, Japan
- Risa Yokokawa Shibata
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- Takuhiro Sonoyama
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- Mari Ariyasu
- Drug Development and Regulatory Science Division, Shionogi & Co., Ltd., Osaka, Japan
- Ayumi Kitano
- KOTAI Biotechnologies, Inc., Osaka, Japan
- Tommy Terooatea
- KOTAI Biotechnologies, Inc., Osaka, Japan
- Jordan Kelly Villa
- KOTAI Biotechnologies, Inc., Osaka, Japan
- Kazuo Yamashita
- KOTAI Biotechnologies, Inc., Osaka, Japan
- Sho Yamasaki
- Laboratory of Molecular Immunology, World Premier International Research Center Initiative (WPI) Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Sho Yamasaki
- Department of Molecular Immunology, Research Institute for Microbial Diseases, Osaka University, Suita, Japan
- Sho Yamasaki
- Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan
- Tomohiro Kurosaki
- Laboratory of Lymphocyte Differentiation, WPI Immunology Frontier Research Center, Osaka University, Osaka, Japan
- Tomohiro Kurosaki
- Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan
- Shinya Omoto
- Vaccine Business Division, Shionogi & Co., Ltd., Osaka, Japan
- DOI
- https://doi.org/10.3389/fimmu.2025.1550279
- Journal volume & issue
-
Vol. 16
Abstract
BackgroundThe durability of vaccine-induced immune memory to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is crucial for preventing infection, especially severe disease.MethodsThis follow-up report from a phase 1/2 study of S-268019-b (a recombinant spike protein vaccine) after homologous booster vaccination confirms its long-term safety, tolerability, and immunogenicity.ResultsBooster vaccination with S-268019-b resulted in an enhancement of serum neutralizing antibody (NAb) titers and a broad range of viral neutralization. Single-cell immune profiling revealed persistent and mature antigen-specific memory B cells and T follicular helper cells, with increased B-cell receptor diversity. The expansion of B- and T-cell repertoires and presence of cross-reactive NAbs targeting conserved epitopes within the receptor-binding domain following a booster accounted for the broad-spectrum neutralizing activity.ConclusionThese findings highlight the potential of S-268019-b to provide broad and robust protection against a range of SARS-CoV-2 variants, addressing a critical challenge in the ongoing fight against coronavirus disease 2019 (COVID-19).
Keywords
